Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
The Journal of Clinical Endocrinology & Metabolism · 21.12.2023 · 109 (1) · 25-35
DOI: 10.1210/clinem/dgad637 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 31.10.2023. Verfasst von Raymond S Douglas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. Hauptthemen laut MEDLINE: Exophthalmos, Graves Ophthalmopathy. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Therapeutics.
Abstract (Originalsprache)
Context
Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high-inflammation TED trials.
Objective
We present data from the first placebo-controlled trial with teprotumumab in chronic/low disease activity TED.
Methods
This randomized double-masked, placebo-controlled trial, conducted at 11 US centers, enrolled adult participants with TED duration of 2 to 10 years, Clinical Activity Score (CAS) ≤ 1 or no additional inflammation or progression in proptosis/diplopia for ≥1 year, proptosis ≥3 mm from before TED and/or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab, and no steroids within 3 weeks of baseline. Patients received (2:1) intravenous teprotumumab or placebo once every 3 weeks (total 8 infusions). The primary endpoint was proptosis (mm) improvement at Week 24. Adverse events (AEs) were assessed.
Results
A total of 62 (42 teprotumumab and 20 placebo) patients were randomized. At Week 24, least squares mean (SE) proptosis improvement was greater with teprotumumab (−2.41 [0.228]) than with placebo (−0.92 [0.323]), difference −1.48 (95% CI −2.28, −0.69; P = .0004). Proportions of patients with AEs were similar between groups. Hyperglycemia was reported in 6 (15%) vs 2 (10%) and hearing impairment in 9 (22%) vs 2 (10%) with teprotumumab and placebo, respectively. AEs led to discontinuation in 1 teprotumumab (left ear conductive hearing loss with congenital anomaly) and 1 placebo patient (infusion-related). There were no deaths.
Conclusion
Teprotumumab significantly improved proptosis vs placebo in longstanding/low inflammation TED, demonstrating efficacy regardless of disease duration/activity. The safety profile was comparable to that previously reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
- John F. Hardesty MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63130, USA.
- Bascom Palmer Eye Institute, University of Miami, Miami, FL 33136, USA.
- Department of Ophthalmology, The University of Tennessee Health Science Center, Hamilton Eye Institute, Memphis, TN 38163, USA.
- Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA 92037, USA.
- Departments of Ophthalmology, Neurology, and Neurosurgery, UC Health Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO 80045, USA.
ORCID-Profile: Raymond S Douglas, Michael Karon
Förderung
- Horizon Therapeutics
Zitieren
APA
Douglas, R. S., Couch, S., Wester, S. T., Fowler, B. T., Liu, C. Y., Subramanian, P. S., Tang, R., Nguyen, Q. T., Maamari, R. N., Ugradar, S., Hsu, K., Karon, M., & Stan, M. N. (2023). Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. The Journal of Clinical Endocrinology & Metabolism, 109(1), 25-35. https://doi.org/10.1210/clinem/dgad637
Vancouver
Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, et al. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. The Journal of Clinical Endocrinology & Metabolism. 2023;109(1):25-35. doi:10.1210/clinem/dgad637
BibTeX
@article{Douglas2023,
author = {Douglas, Raymond S and Couch, Steven and Wester, Sara T and Fowler, Brian T and Liu, Catherine Y and Subramanian, Prem S and Tang, Rosa and Nguyen, Quang T and Maamari, Robi N and Ugradar, Shoaib and Hsu, Kate and Karon, Michael and Stan, Marius N},
title = {Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {109},
number = {1},
pages = {25--35},
doi = {10.1210/clinem/dgad637}
}
EUVIMED